SMS Pharmaceuticals , a prominent player in the pharmaceutical industry, has seen a significant change in its shareholding structure. Vistra ITCL (India) Limited, acting in its capacity as a Debenture Trustee, has increased its stake in the company through a share pledge transaction.

Key Highlights

• Vistra ITCL acquired 30,00,000 shares of SMS Pharmaceuticals through encumbrance or pledge.
• The acquisition represents 3.38% of SMS Pharmaceuticals' total share capital.
• Vistra's total shareholding in SMS Pharmaceuticals increased from 21.53% to 24.91% following this transaction.

Transaction Details

Vistra ITCL (India) Limited, in its role as a Debenture Trustee, received a pledge of 30,00,000 equity shares of SMS Pharmaceuticals Limited. This pledge increased Vistra's holding in the company by 3.38 percentage points, bringing their total stake to 24.91% of the company's share capital.

Company Overview

SMS Pharmaceuticals Limited has an equity share capital comprising 8,86,52,030 shares, each with a face value of Rs. 1. The company's shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

Shareholding Structure

The following table illustrates the change in Vistra ITCL's shareholding in SMS Pharmaceuticals:

Regulatory Compliance

Vistra ITCL has made this disclosure as a precautionary measure in its capacity as security trustee and debenture trustee. The company clarified that while the primary compliance responsibility lies with the lender and debenture holder, they have taken this step to ensure transparency and adherence to regulatory requirements.

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, demonstrating the company's commitment to maintaining open communication with its shareholders and regulatory bodies.

This development marks a significant shift in the ownership structure of SMS Pharmaceuticals Limited and may be of interest to investors and market analysts tracking the pharmaceutical sector.

SMS Pharmaceuticals Limited, a leading pharmaceutical company, has reported strong financial results for the first quarter of fiscal year 2026, showcasing impressive growth across key metrics.

Financial Highlights

• Revenue from operations increased by 19% year-on-year to ₹196.05 crore
• Profit After Tax (PAT) grew by 24% YoY to ₹20.50 crore
• EBITDA rose by 17% YoY to ₹39.37 crore
• PAT margin maintained at a stable 10.00%
• EBITDA margin remained steady at 20.00%

Segment Performance

The company's growth was primarily driven by two key segments:

1. Anti-diabetic Segment: Witnessed a remarkable 45% YoY increase, reaching ₹65.16 crore
2. ARV Products: Experienced a substantial surge of 199% YoY, amounting to ₹38.48 crore

Operational Achievements and Future Outlook

SMS Pharmaceuticals has made significant strides in its operational capabilities and future growth plans:

• Successfully commissioned a backward integration project for key APIs, expected to improve margins in upcoming quarters
• Executing a ₹250 crore capacity expansion program, funded through a combination of internal accruals and debt
• Doubling R&D investment over the next 18 months to drive innovation and product development
• Targeting 20% revenue growth for FY26 with EBITDA margins above 20.00%
• Aiming for approximately 30 regulatory submissions over the next three years

Management Commentary

The management of SMS Pharmaceuticals expressed satisfaction with the company's performance, attributing the strong results to higher volumes and robust demand for key Active Pharmaceutical Ingredients (APIs). The company's focus on expanding its product portfolio and enhancing manufacturing capabilities is expected to drive sustained growth in the coming quarters.

Conclusion

SMS Pharmaceuticals' Q1FY26 results demonstrate the company's ability to capitalize on market opportunities and execute its growth strategy effectively. With a clear focus on expanding capacity, investing in R&D, and targeting key pharmaceutical segments, the company is well-positioned to maintain its growth trajectory and strengthen its market presence in the pharmaceutical industry.

Investors and industry observers will likely keep a close watch on SMS Pharmaceuticals' progress as it works towards its ambitious growth targets and expands its regulatory submissions in the coming years.